Technical Analysis for NVCR - NovoCure Limited
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 12.64 | 3.31% | 0.41 |
NVCR closed up 3.31 percent on Friday, April 26, 2024, on 57 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: May 2
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Wide Bands | Range Expansion | 3.31% | |
Oversold Stochastic | Weakness | 3.31% | |
NR7 | Range Contraction | 2.39% | |
Narrow Range Bar | Range Contraction | 2.39% | |
Inside Day | Range Contraction | 2.39% | |
Wide Bands | Range Expansion | 2.39% | |
Oversold Stochastic | Weakness | 2.39% | |
Slingshot Bearish | Bearish Swing Setup | 4.81% |
Alert | Time |
---|---|
Up 3% | 2 days ago |
60 Minute Opening Range Breakout | 2 days ago |
Up 2% | 2 days ago |
Rose Above Previous Day's High | 2 days ago |
Rose Above 10 DMA | 2 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/02/2024
NovoCure Limited develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (TTFields). The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. NovoCure Limited also conducts clinical trials for the use of TTFields in brain metastases, advanced non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, as well as in European Union member states, Switzerland, and Japan. NovoCure Limited was founded in 2000 and is based in Saint Helier, Channel Islands.
Sector: Healthcare
Industry: Medical Instruments & Supplies
Keywords: Medicine Cancer Clinical Medicine Oncology Tumor Non Small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Blastoma Small Cell Lung Cancer Glioblastoma Brain Tumor Solid Tumor Cancers Aging Associated Diseases Metastases Brain Cancer Mesothelioma
Classification
Sector: Healthcare
Industry: Medical Instruments & Supplies
Keywords: Medicine Cancer Clinical Medicine Oncology Tumor Non Small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Blastoma Small Cell Lung Cancer Glioblastoma Brain Tumor Solid Tumor Cancers Aging Associated Diseases Metastases Brain Cancer Mesothelioma
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 83.6 |
52 Week Low | 10.87 |
Average Volume | 1,338,892 |
200-Day Moving Average | 17.67 |
50-Day Moving Average | 14.43 |
20-Day Moving Average | 13.31 |
10-Day Moving Average | 12.25 |
Average True Range | 0.73 |
RSI (14) | 42.86 |
ADX | 15.76 |
+DI | 19.70 |
-DI | 23.99 |
Chandelier Exit (Long, 3 ATRs) | 13.86 |
Chandelier Exit (Short, 3 ATRs) | 13.89 |
Upper Bollinger Bands | 15.59 |
Lower Bollinger Band | 11.03 |
Percent B (%b) | 0.35 |
BandWidth | 34.28 |
MACD Line | -0.64 |
MACD Signal Line | -0.60 |
MACD Histogram | -0.0383 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 13.60 | ||||
Resistance 3 (R3) | 13.49 | 13.07 | 13.44 | ||
Resistance 2 (R2) | 13.07 | 12.83 | 13.12 | 13.38 | |
Resistance 1 (R1) | 12.85 | 12.68 | 12.96 | 12.96 | 13.33 |
Pivot Point | 12.43 | 12.43 | 12.49 | 12.48 | 12.43 |
Support 1 (S1) | 12.21 | 12.19 | 12.32 | 12.32 | 11.94 |
Support 2 (S2) | 11.79 | 12.04 | 11.84 | 11.89 | |
Support 3 (S3) | 11.57 | 11.79 | 11.84 | ||
Support 4 (S4) | 11.68 |